11月6日，药明生物盘中下跌5.46%，报46.94港元，成交额2.97亿港元。
消息面上，公司此前获花旗纳入90天上行催化剂观察名单，认为其第四季度或上调整体指引；同时，药明生物与费森尤斯达成未来10年最多37款生物类似药候选产品独家开发合作，被视为生物类似药领域迄今规模最大的开发协议。
不过，相关利好已在前两个交易日推动股价连续活跃，当前回落更多反映短线资金兑现压力；从板块看，药明康德、药明合联、康龙化成等同类个股亦走弱。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.